Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Has Consensus Price Target of $23.40 According to Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned an average recommendation of “Reduce” from the eighteen brokerages that are presently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $23.40.

Several research analysts recently issued reports on the stock. Royal Bank Of Canada increased their price target on shares of Sarepta Therapeutics from $17.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Friday. Weiss Ratings downgraded Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 28th. Benchmark reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th. Robert W. Baird set a $18.00 target price on Sarepta Therapeutics in a report on Friday. Finally, William Blair upgraded Sarepta Therapeutics to a “hold” rating in a report on Wednesday, September 23rd.

Sarepta Therapeutics Trading Down 3.3%

SRPT opened at $17.24 on Friday. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a 52 week low of $14.68 and a 52 week high of $24.68. The stock has a market cap of $1.82 billion, a PE ratio of -12.58, a PEG ratio of 0.35 and a beta of 0.45. The business has a 50 day moving average of $19.06 and a 200-day moving average of $18.62.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. The company had revenue of $381.35 million for the quarter, compared to analysts’ expectations of $352.20 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. The firm’s revenue for the quarter was down 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.13) earnings per share. Equities research analysts predict that Sarepta Therapeutics will post 3.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. BlackRock Inc. bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $341,339,000. First Trust Advisors LP boosted its position in shares of Sarepta Therapeutics by 107.6% during the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after buying an additional 2,143,211 shares during the last quarter. Bank of America Corp DE bought a new stake in Sarepta Therapeutics in the 2nd quarter worth about $36,946,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Sarepta Therapeutics during the 2nd quarter valued at about $17,494,000. Finally, Legal & General Group Plc bought a new position in Sarepta Therapeutics during the 2nd quarter valued at about $15,771,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches.

The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.

Sarepta is headquartered in Cambridge, Massachusetts.